Back To Search Instructions
Protocols
8 protocols meet the specified criteria
Disease Site: Myeloid and Monocytic Leukemia
Protocol No.TitleStatus
05-0226-04Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
09-0679-04A Phase II Study Of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) For Treatment Of Hematologic Malignancies And Hematopoietic Failure StatesOpen
12-0148-04A multicenter safety study of unlicensed investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patientsOpen
12-0222-04SWOG1117, "A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)".Open
12-0934-10E2906 Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ¡Ý60 Years)Open
13-0057-10SWOG 1203 A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)Open
20120158CC-5013-AML-001 A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL, PARALLEL-GROUP STUDY OF A LENALIDOMIDE (REVLIMID®) REGIMEN OR A SEQUENTIAL AZACITIDINE (VIDAZA®) PLUS LENALIDOMIDE (REVLIMID®) REGIMEN VERSUS AN AZACITIDINE (VIDAZA®) REGIMEN FOR THERAPY OF OLDER SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Open
NMDP2011-0264A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, version 3.0 Open